SRL
VTGN icon

Scientech Research LLC’s VistaGen Therapeutics VTGN Stock Holding History

Scientech Research LLC’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.84K Buy
+30,283
New +$18.3K 0.01% 222

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Scientech Research LLC's VTGN Position: Q2 2026 in Review

Scientech Research LLC opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 30,283 shares worth $6.84K. The stake represents 0.01% of the portfolio and ranks #222 among its holdings.

49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Scientech Research LLC held 30,283 shares of VistaGen Therapeutics worth $6.84K as of Q2 2026.
  • VistaGen Therapeutics was a new Scientech Research LLC position in Q2 2026.
  • VistaGen Therapeutics made up 0.01% of Scientech Research LLC's portfolio in Q2 2026, its #222 holding.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.